Progesterone drops dramatically during the menopausal transition, eventually falling to near-zero levels. While estrogen gets most of the attention in conversations about menopause, progesterone actually starts declining first, often by the late 30s, and its loss drives many of the symptoms people associate with this stage of life.
Why Progesterone Disappears
Almost all of your progesterone comes from a temporary structure in the ovary called the corpus luteum, which forms each month after you ovulate. Once the egg is released, the leftover follicle transforms into this small hormone-producing gland that pumps out progesterone for about 12 to 14 days. If pregnancy doesn’t occur, the corpus luteum breaks down, progesterone drops, and you get your period. This cycle repeats month after month for decades.
The key point: no ovulation means no corpus luteum, and no corpus luteum means virtually no progesterone. As you move through perimenopause, ovulation becomes irregular and eventually stops altogether. Some cycles produce an egg, others don’t. The months without ovulation are months without meaningful progesterone production. By the time you reach menopause (defined as 12 consecutive months without a period), ovulation has ceased entirely, and so has the primary source of this hormone.
Your adrenal glands do produce small amounts of progesterone, and research measuring steroid levels in postmenopausal women confirms that baseline progesterone doesn’t drop to absolute zero. But these trace amounts are biologically insignificant compared to what the corpus luteum once generated.
How Far Progesterone Falls
The numbers make the decline concrete. During the luteal phase of a normal menstrual cycle, when the corpus luteum is active, progesterone levels range from roughly 300 to 2,500 ng/dL. After menopause, levels fall below 40 ng/dL. That’s a drop of at least 85% and often more than 98%. By comparison, estrogen also declines significantly during menopause, but the proportional loss of progesterone is steeper.
This decline doesn’t happen overnight. By the late 30s, progesterone production begins to taper. Perimenopause, the transition period leading up to menopause, averages three to four years but can last anywhere from a few months to a full decade. During this window, progesterone levels swing unpredictably. You might have a normal ovulatory cycle one month followed by two or three cycles without ovulation. This inconsistency is part of why perimenopausal symptoms can feel so erratic.
Effects on Mood and Sleep
Progesterone has a calming effect on the brain. It gets converted into metabolites that interact with the same brain receptors targeted by anti-anxiety medications. When progesterone levels become erratic and then collapse, that calming signal weakens. Johns Hopkins Medicine notes that falling progesterone levels can trigger irritability, anxiety, and mood swings that make you less able to cope with things you’d normally let roll off your back.
Sleep disruption is another common consequence. Progesterone’s brain-calming metabolites also promote sleep, and their decline during perimenopause and menopause contributes to the insomnia and fragmented sleep many women experience. These sleep problems aren’t purely the result of hot flashes (though those don’t help). The loss of progesterone’s sedative-like activity plays its own independent role.
Effects on Bone Health
Most people know that estrogen loss after menopause accelerates bone loss. Fewer realize that progesterone plays a distinct and complementary role in keeping bones strong. Estrogen’s job is primarily to slow bone breakdown. Progesterone stimulates bone-building cells called osteoblasts, the cells responsible for forming new bone tissue.
Lab studies on human bone cells show this clearly. When exposed to normal physiological levels of progesterone for 21 days, osteoblast activity increased 2.7-fold. The effect is dose-dependent and works independently of estrogen, meaning progesterone contributes to bone formation on its own. Studies tracking women across different life stages, from adolescence through postmenopause, consistently point to progesterone as an active player in maintaining bone density and preventing osteoporosis. The accelerated bone loss after menopause reflects the combined withdrawal of both hormones, not just estrogen.
The Unopposed Estrogen Problem
One of progesterone’s most important jobs is counterbalancing estrogen’s effect on the uterine lining. Estrogen stimulates the cells of the endometrium to grow and multiply. Progesterone acts as a brake, stopping that growth and triggering the organized shedding that becomes a period. Without progesterone to oppose it, estrogen can drive unchecked cell proliferation in the uterine lining, increasing the chance of genetic errors and, eventually, cancer.
This matters most during perimenopause, when estrogen levels can actually spike unpredictably even as progesterone is disappearing. You can end up with months of estrogen stimulation and little or no progesterone to counteract it. Research from the National Cancer Institute found that women taking estrogen-only hormone therapy (without a progestin) had a 74% higher risk of endometrial cancer compared to women who never used hormones. For long-term use of 10 years or more, the risk jumped to nearly four times higher. Adding a progestin to the regimen substantially reduced this risk, and the more days per month the progestin was taken, the greater the protection.
After menopause, when both estrogen and progesterone are low, this dynamic becomes less of a concern for women not taking hormones. But for anyone considering estrogen therapy who still has a uterus, progesterone (or a synthetic progestin) is considered essential.
Progesterone in Hormone Therapy
When progesterone is prescribed as part of menopausal hormone therapy, it typically serves two purposes: protecting the uterine lining from unopposed estrogen, and potentially easing symptoms like sleep disruption and anxiety that stem from progesterone’s own decline.
Not all forms of progesterone are the same. Micronized progesterone, which is chemically identical to what your body produces, appears to carry a different risk profile than synthetic progestins. A meta-analysis comparing the two found that women using estrogen combined with micronized progesterone had a 33% lower risk of breast cancer compared to those using estrogen with synthetic progestins. In fact, the combination of estrogen with micronized progesterone showed no significant increase in breast cancer risk at all, while synthetic progestins trended toward a higher risk.
The differences extend to cardiovascular markers as well. One well-known trial found that micronized progesterone, unlike the most commonly prescribed synthetic progestin, did not negate estrogen’s beneficial effects on HDL cholesterol (the protective kind). However, long-term data comparing actual heart disease outcomes between the two types remain limited.
These distinctions matter if you’re weighing hormone therapy options. The type of progesterone prescribed, how many days per month it’s taken, and whether you still have your uterus all factor into the risk-benefit calculation.